Indication: Relapsed/Refractory Multiple Myeloma
Title: BOSTON: Bortezomib, selinexor, and Dexamethasone in Patients with Multiple Myeloma
BOSTON is a Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study that will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade®) plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with relapsed / refractory multiple myeloma who have received 1 to 3 prior anti-multiple myeloma (MM) regimens.
Velcade® plus low-dose dexamethasone is a standard therapy for previously treated multiple myeloma that is given by injection two times a week. Unlike other drugs used to treat multiple myeloma, selinexor is taken orally.
Patients enrolled in the BOSTON study will receive either Velcade® plus low-dose dexamethasone (standard therapy given on the recommended schedule) or selinexor plus standard therapy taken one time per week.
This trial is for selinexor.
|Preclinical||Phase I||Phase II||Phase III|